Filings monitor · STE

What STERIS plc's SEC filings said

10-Q for 2026Q3, filed 5 Nov 2026. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

1. Acquisition / Partnership / Divestiture71 · importance in its document · 10-Q · 2026Q3
   On October 11, 2026, STERIS entered into an agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, subject to customary adjustments, plus potential earnout consideration of up to $150.0 million. The company…
2. Capital Return Program69 · importance in its document · 10-Q · 2026Q3
   STERIS repurchased 0.9 million ordinary shares for $200.0 million through its share repurchase program in the first six months of fiscal 2027, compared with 0.4 million shares for $100.0 million in the prior-year period. Separately, it…
3. Operating Expense Trends68 · importance in its document · 8-K exhibit · 4 Nov 2026
   Second-quarter SG&A expense increased to $366.0 million from $349.7 million, a 4.7% rise. Research and development expense increased 11.7% to $31.5 million from $28.2 million. Restructuring expense was $19.1 million compared with $2.2…
4. Guidance revised (direction not stated)55 · rule score among filings · 8-K Item 2.02 · 4 Nov 2026
   Fiscal 2027 Outlook The Company is updating its prior outlook for revenue and earnings for fiscal 2027.
5. Segment Revenue Performance54 · importance in its document · 10-Q · 2026Q3
   For the six months ended September 30, 2026, Healthcare revenue rose 8.1% to $2,170.8 million, AST revenue rose 5.4% to $593.2 million, and Life Sciences revenue rose 13.3% to $317.4 million. Healthcare growth reflected mid-single-digit…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 5 Nov 2026

Full report · Filing on EDGAR

• Acquisition / Partnership / DivestitureImportance 71
  On October 11, 2026, STERIS entered into an agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing, subject to customary adjustments, plus potential earnout consideration of up to $150.0…
• Capital Return ProgramImportance 69
  STERIS repurchased 0.9 million ordinary shares for $200.0 million through its share repurchase program in the first six months of fiscal 2027, compared with 0.4 million shares for $100.0 million in the prior-year…
• Segment Revenue PerformanceImportance 54 · +1 more on this subject
  For the six months ended September 30, 2026, Healthcare revenue rose 8.1% to $2,170.8 million, AST revenue rose 5.4% to $593.2 million, and Life Sciences revenue rose 13.3% to $317.4 million. Healthcare growth…
• Segment ProfitabilityImportance 54
  For the six months ended September 30, 2026, operating income increased 7.0% to $529.4 million in Healthcare, 4.0% to $275.1 million in AST, and 16.0% to $137.5 million in Life Sciences. Healthcare’s six-month…
• Geographic Market CommentaryImportance 54
  For the six months ended September 30, 2026, U.S. revenue increased 7.8% to $2,264.9 million, while revenue from other foreign locations increased 8.7% to $761.4 million. Growth in other foreign locations reflected…
• North Carolina Chemistry ConsolidationImportance 52
  The Fiscal 2027 Manufacturing Restructuring Plan will consolidate formulated-chemistry manufacturing and distribution at a new North Carolina Center of Excellence and close facilities in St. Louis, Missouri, and…
• Capital Expenditures and Free Cash FlowImportance 49
  For the first six months of fiscal 2027, operating cash flow was $656.1 million and free cash flow was $492.5 million, down from $707.8 million and $527.7 million, respectively, a year earlier. The decreases reflected…
• Portfolio and Organizational OptimizationImportance 46
  During the second quarter of fiscal 2027, STERIS approved a targeted plan covering facility realignment, product rationalization, and organizational realignment. The company anticipates approximately $45 million in…
• Income Tax Rate ChangesImportance 40
  The effective income tax rate increased to 25.7% in the three months ended September 30, 2026, from 23.9% a year earlier, and to 26.1% for the six months from 23.6%. Six-month income tax expense rose 27.9% to $146.4…
• Liquidity and Debt PositionImportance 36
  Commercial commitments were approximately $160.3 million at September 30, 2026, down $1.0 million from March 31, 2026. STERIS had no outstanding borrowings under its Revolving Credit Facility and $5.3 million of…
• Operating Expense TrendsImportance 29
  For the six months ended September 30, 2026, SG&A increased 4.6% to $735.7 million, primarily from compensation and benefit costs, professional fees, and dealer commissions, partly offset by favorable foreign currency…
• Gross Margin DriversImportance 25
  Gross profit percentage for the second quarter of fiscal 2027 increased to 44.7% from 44.2%, while six-month gross profit percentage increased to 45.3% from 44.7%. In the quarter, pricing added 130 basis points, tariff…

8-K filings last 12 months

• Guidance revised (direction not stated) · Restructuring, repeated4 Nov 2026 · 8-K Items 2.02, 2.05 · Flagged · rule score 55
  “Fiscal 2027 Outlook The Company is updating its prior outlook for revenue and earnings for fiscal 2027.”
  Read from the attached exhibit: Operating Expense Trends · Capital Return Program · Guidance / Outlook
• New debt4 Nov 2026 · 8-K Items 1.01, 2.03 · Flagged · rule score 50
  “On November 4, 2026, STERIS plc (“STERIS”), STERIS Corporation (“Corporation”), STERIS Limited (“Limited”) and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement (the “New…”
• Restructuring, repeated · Results (release not read)5 Aug 2026 · 8-K Items 2.02, 2.05 · Routine · rule score 40
  Read from the attached exhibit: Capital Expenditure Outlook · Guidance / Outlook · Capital Return Program
• Results (release not read)11 May 2026 · 8-K Item 2.02 · Routine · rule score 20
• Management change (filing not read)7 May 2026 · 8-K Item 5.02 · Routine · rule score 20
• Management change (filing not read)6 Apr 2026 · 8-K Item 5.02 · Routine · rule score 20
• Results (release not read)4 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Earlier reports

• 10-Q · 2026Q2filed 7 Aug 2026
  Capital Return Program · Segment Revenue Performance · Income Tax Rate Changes

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.